385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

BACKGROUND: A variant-adapted bivalent BNT162b2 mRNA vaccine (bivalent BNT162b2) comprising original SARS-CoV-2 and Omicron BA.4/BA.5 spike proteins is authorized by the US FDA from 6 months of age as a primary series or as booster doses. We studied whether bivalent BNT162b2 booster generates improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulsen, Grant C, Sher, Lawrence, Sabharwal, Charu, Kitchin, Nicholas, Hill, Sungeen, Wasserman, Emily, Xu, Xia, Maldonado, Yvonne A, Barnett, Elizabeth, Englund, Janet A, Walter, Emmanuel, Munoz, Flor M, Simoes, Eric, Talaat, Kawsar R, Kamidani, Satoshi, Moyer, Lisa, Parikh, Vrunda, Ma, Hua, Wang, Xingbin, Koury, Kenneth, Anderson, Annaliesa S, Swanson, Kena A, Gurtman, Alejandra C, Gruber, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678111/
http://dx.doi.org/10.1093/ofid/ofad500.455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678111/
http://dx.doi.org/10.1093/ofid/ofad500.455

Ejemplares similares